Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC (2022)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; CASTRO JUNIOR, GILBERTO DE - FM ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP ; MARIN, JOSÉ FLÁVIO GOMES - FM
- Unidades: FMRP; FM
- DOI: 10.1177/17588359221138386
- Subjects: BIOMARCADORES; GLICOSE; IMUNOTERAPIA; NEOPLASIAS PULMONARES
- Keywords: 18F-FDG PET/CT; Warburg effect; Biomarkers; Glycolysis; Immunotherapy; Non-small-cell lung cancer
- Language: Inglês
- Imprenta:
- Source:
- Título: Therapeutic Advances in Medical Oncology
- ISSN: 1758-8359
- Volume/Número/Paginação/Ano: v. 14, art. 17588359221138386, p. 1-13, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
SILVA, Saulo Brito et al. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, v. 14, p. 1-13, 2022Tradução . . Disponível em: https://doi.org/10.1177/17588359221138386. Acesso em: 28 dez. 2025. -
APA
Silva, S. B., Wanderley, C. W. S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. C. T. do, Antonacio, F. F., et al. (2022). Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, 14, 1-13. doi:10.1177/17588359221138386 -
NLM
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1177/17588359221138386 -
Vancouver
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1177/17588359221138386 - Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors
- Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
- Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications
- Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
- Desenvolvimento e aplicação de método semiquantitativo do esqueleto total em exames de 18F-NaF PET/CT: estabelecimento de valores normais em pacientes não metastáticos e avaliação prognóstica em pacientes com metástases ósseas
- Platelets fuel the inflammasome activation of innate immune cells
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
Informações sobre o DOI: 10.1177/17588359221138386 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003153548.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
